NCT00474812View on ClinicalTrials.gov

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2014

Conditions
Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

dasatinib

PROCEDURE

laboratory biomarker analysis

Correlative study

PROCEDURE

physiologic testing

Correlative study

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00474812 - Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter